Gene replacement therapy using adeno-associated virus (AAV) based vectors to deliver functional F8 and F9 genes to the liver have resulted in stable and therapeutic FVIII and FIX protein levels in adult hemophilia patients (7), with several candidates advancing into phase III clinical trials (8). This evidence concerns the gene F9 and hemophilia.